Declaretimi 58: Dapagliflozin Cuts Heart Failure In Diabetes | Latest News RSS feed

Declaretimi 58: Dapagliflozin Cuts Heart Failure In Diabetes - Latest News


Less Heart Failure Hospitalization on Dapagliflozin in Diabetes at Any LVEF, Declares DECLARE-TIMI 58

NEW ORLEANS — Patients with type 2 diabetes who received dapagliflozin (Farxiga/Forxiga, AstraZeneca) in the DECLARE-TIMI 58 trial showed a reduced risk for heart-failure (HF) hospitalization, ... read more

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

NEW ORLEANS, LA—Two new analyses from the DECLARE-TIMI 58 ... dapagliflozin (Farxiga; AstraZeneca) in patients with type 2 diabetes and either high cardiovascular risk or established ASCVD reduced the ... read more

Diabetes drug effective against heart failure in wide spectrum of patients

New Orleans, LA (Mar 18, 2019) - The cardiovascular benefits of the diabetes drug dapagliflozin ... in patients with heart failure, which should shed further light on the benefits observed in this ... read more

Looking for another news?


Diabetes Drug Farxiga Cuts Heart Risks in Topline Results

The diabetes drug dapagliflozin (Farxiga, AstraZeneca) did not increase the the risk of major cardiovascular (CV) events and produced benefits for heart failure ... Full results from the trial, called ... read more


Dapagliflozin May Lower Heart Failure Hospitalizations in Patients With Diabetes

2 Despite these findings, dapagliflozin 10mg once per day was associated with lower rates of cardiovascular death or hospitalization for heart failure (HF ... placebo-controlled phase 3 trial (DECLARE ... read more

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes

CHICAGO — Dapagliflozin (Farxiga/Forxiga, AstraZeneca) showed a nonsignificant trend toward a reduced rate of major adverse cardiac events (MACE) but significantly reduced hospitalization for heart ... read more

First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

--(BUSINESS WIRE)--Positive results from a pre-specified sub-analysis of the Phase III DECLARE-TIMI 58 trial showed that FARXIGA (dapagliflozin ... failure and MACE. Heart failure is one of the most ... read more

Diabetes drug effective against heart failure in wide spectrum of patients

The cardiovascular benefits of the diabetes ... the DECLARE-TIMI 58 trial, which reported in 2018 that dapagliflozin, part of a class of drugs known as SGLT2 inhibitors, reduced the composite primary ... read more

Dapagliflozin Gets Partial Win in DECLARE-TIMI 58

Dapagliflozin (Farxiga) reduces cardiovascular outcomes in high-risk patients with type 2 diabetes, according to top-line results of the phase III DECLARE-TIMI 58 trial ... of CV death or ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us